EDGAR Filing Documents for 0001193125-21-177240

Form 8-K - Current report:

SEC Accession No. 0001193125-21-177240

Filing Date

2021-05-28

Accepted

2021-05-28 17:26:36

Documents

Period of Report

2021-05-24

Items

Item 1.02: Termination of a Material Definitive Agreement
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	d57577d8k.htm	8-K	160339
2	EX-3.1	d57577dex31.htm	EX-3.1	57233
3	EX-3.2	d57577dex32.htm	EX-3.2	177854
4	EX-10.6	d57577dex106.htm	EX-10.6	35109
5	EX-10.7	d57577dex107.htm	EX-10.7	42351
6	EX-10.8	d57577dex108.htm	EX-10.8	175585
7	EX-10.9	d57577dex109.htm	EX-10.9	14495
8	EX-10.33	d57577dex1033.htm	EX-10.33	35466
9	EX-10.34	d57577dex1034.htm	EX-10.34	14899
10	EX-16.1	d57577dex161.htm	EX-16.1	3022
11	EX-21.1	d57577dex211.htm	EX-21.1	2541
12	GRAPHIC	g57577dsp1a.jpg	GRAPHIC	4882
13	GRAPHIC	g57577dsp1b.jpg	GRAPHIC	2594
14	GRAPHIC	g57577dsp1c.jpg	GRAPHIC	10088
15	GRAPHIC	g57577snap0001.jpg	GRAPHIC	24896
	Complete submission text file	0001193125-21-177240.txt		779270

Mailing Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801

Business Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801 484-254-6134

NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)